Literature DB >> 14765341

Invasive pneumococcal disease among Navajo adults, 1989-1998.

James P Watt1, Katherine L O'Brien, Andrea L Benin, Cynthia G Whitney, Katherine Robinson, Alan J Parkinson, Raymond Reid, Mathuram Santosham.   

Abstract

Compared with white and black persons in the United States, some Native American groups are at increased risk for invasive pneumococcal disease (IPD). To characterize the epidemiology of IPD among Navajo adults, we conducted active surveillance for IPD on the Navajo Nation and reviewed medical records of patients with IPD. For 1997-1998, the annual incidence (cases per 100,000 persons) was 56 for Navajos aged 18-64 years and 190 for Navajos aged > or =65 years. The corresponding rates were 10 and 57 for white and 44 and 82 for black persons in the United States. The case-fatality rate was 14%. Eighty percent of cases were caused by serotypes included in the 23-valent pneumococcal polysaccharide vaccine. Navajo adults have rates of IPD that are 3-5-fold higher than those of the general US population. Additional research is needed to understand the reasons for this elevated risk and to develop prevention strategies.

Entities:  

Mesh:

Year:  2004        PMID: 14765341     DOI: 10.1086/381198

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  9 in total

1.  Pandemic influenza preparedness and vulnerable populations in tribal communities.

Authors:  Amy V Groom; Cheyenne Jim; Mic Laroque; Cheryl Mason; Joe McLaughlin; Lisa Neel; Terry Powell; Thomas Weiser; Ralph T Bryan
Journal:  Am J Public Health       Date:  2009-05-21       Impact factor: 9.308

2.  Infectious disease hospitalizations among older American Indian and Alaska Native adults.

Authors:  Robert C Holman; Aaron T Curns; Rosalyn J Singleton; James J Sejvar; Jay C Butler; Edna L Paisano; Lawrence B Schonberger; James E Cheek
Journal:  Public Health Rep       Date:  2006 Nov-Dec       Impact factor: 2.792

3.  Pneumonia and influenza mortality among American Indian and Alaska Native people, 1990-2009.

Authors:  Amy V Groom; Thomas W Hennessy; Rosalyn J Singleton; Jay C Butler; Stephen Holve; James E Cheek
Journal:  Am J Public Health       Date:  2014-04-22       Impact factor: 9.308

4.  Immune Responses to pneumococcal vaccines in children and adults: Rationale for age-specific vaccination.

Authors:  M A Julie Westerink; Harry W Schroeder; Moon H Nahm
Journal:  Aging Dis       Date:  2011-07-20       Impact factor: 6.745

5.  Increased influenza-related healthcare utilization by residents of an urban aboriginal community.

Authors:  K M Charland; J S Brownstein; A Verma; T Brewer; S Jones; A Gatewood Hoen; D L Buckeridge
Journal:  Epidemiol Infect       Date:  2011-01-20       Impact factor: 2.451

6.  Race-related differences in functional antibody response to pneumococcal vaccination in HIV-infected individuals.

Authors:  Myroslawa Happe; Devadoss J Samuvel; Jennifer A Ohtola; Jeff E Korte; M A Julie Westerink
Journal:  Vaccine       Date:  2019-02-21       Impact factor: 3.641

7.  Prevalence and Antimicrobial Susceptibility of Streptococcus pneumoniae Isolated from Clinical Samples in the Past 8 Years in Korea.

Authors:  Jae Soo Kim; Bo Kyeung Jung; Jong Wan Kim; Ga Yeon Kim
Journal:  Biomed Res Int       Date:  2021-04-28       Impact factor: 3.411

8.  Naturally acquired antibodies against 7 Streptococcus pneumoniae serotypes in Indigenous and non-Indigenous adults.

Authors:  Gabrielle N Gaultier; Eli B Nix; Joelle Thorgrimson; Douglas Boreham; William McCready; Marina Ulanova
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

9.  Comparative immunogenicity of 7 and 13-valent pneumococcal conjugate vaccines and the development of functional antibodies to cross-reactive serotypes.

Authors:  Lindsay R Grant; Sarah E O'Brien; Polly Burbidge; Mitch Haston; Marta Zancolli; Lucy Cowell; Marina Johnson; Robert C Weatherholtz; Raymond Reid; Mathuram Santosham; Katherine L O'Brien; David Goldblatt
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.